A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

PHASE3TerminatedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

PD 0332334

Capsules, oral, 175 mg BID, 8 weeks with 2 week taper

DRUG

PD 0332334

Capsules, oral, 225 mg BID, 8 weeks with 2 week taper

DRUG

PD 0332334

Capsules, oral, 75 mg BID, 8 weeks with 2 week taper

DRUG

Paroxetine

Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper

DRUG

Placebo

Capsules, oral, placebo bid, 8 weeks with 2 week taper

Trial Locations (52)

1095

Pfizer Investigational Site, Budapest

1137

Pfizer Investigational Site, Budapest

10023

Pfizer Investigational Site, New York

10126

Pfizer Investigational Site, Torino

10454

Pfizer Investigational Site, The Bronx

10467

Pfizer Investigational Site, The Bronx

11235

Pfizer Investigational Site, Brooklyn

19004

Pfizer Investigational Site, Bala-Cynwyd

19063

Pfizer Investigational Site, Media

19104

Pfizer Investigational Site, Philadelphia

19136

Pfizer Investigational Site, Philadelphia

19401

Pfizer Investigational Site, Norristown

21208

Pfizer Investigational Site, Baltimore

22903

Pfizer Investigational Site, Charlottesville

22911

Pfizer Investigational Site, Charlottesville

27607

Pfizer Investigational Site, Raleigh

29201

Pfizer Investigational Site, Columbia

32701

Pfizer Investigational Site, Altamonte Springs

32751

Pfizer Investigational Site, Maitland

33126

Pfizer Investigational Site, Miami

33143

Pfizer Investigational Site, Miami

Pfizer Investigational Site, South Miami

38117

Pfizer Investigational Site, Memphis

43609

Pfizer Investigational Site, Toledo

43623

Pfizer Investigational Site, Toledo

47802

Pfizer Investigational Site, Terre Haute

63301

Pfizer Investigational Site, Saint Charles

66212

Pfizer Investigational Site, Overland Park

66606

Pfizer Investigational Site, Topeka

71104

Pfizer Investigational Site, Shreveport

73008

Pfizer Investigational Site, Bethany

75231

Pfizer Investigational Site, Dallas

77566

Pfizer Investigational Site, Lake Jackson

78229

Pfizer Investigational Site, San Antonio

78756

Pfizer Investigational Site, Austin

80239

Pfizer Investigational Site, Denver

85340

Pfizer Investigational Site, Litchfield Park

87109

Pfizer Investigational Site, Albuquerque

89146

Pfizer Investigational Site, Las Vegas

91106

Pfizer Investigational Site, Pasadena

92374

Pfizer Investigational Site, Redlands

92626

Pfizer Investigational Site, Costa Mesa

95123

Pfizer Investigational Site, Catania

142601

Pfizer Investigational Site, Khotkovo, Moscow Region

06360

Pfizer Investigational Site, Norwich

02135

Pfizer Investigational Site, Boston

08021

Pfizer Investigational Site, Clementon

08046

Pfizer Investigational Site, Willingboro

05401

Pfizer Investigational Site, Burlington

53188-1660

Pfizer Investigational Site, Waukesha

135-710

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00658008 - A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1) | Biotech Hunter | Biotech Hunter